Tumor Biology

, Volume 36, Issue 1, pp 21–31 | Cite as

Targeting platelet-derived growth factor (PDGF) signaling in gastrointestinal cancers: preclinical and clinical considerations

Review

Abstract

The prognosis of advanced gastrointestinal malignancies has been generally dreadful prompting robust search for better, more personalized, and more tailored treatments. In recent years, important signaling pathways leading to tumor progression and metastasis have been discovered with the subsequent development of targeted therapies to target these pathways. These include epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), mammalian target of rapamycin (mTOR), and mesenchymal epithelial transition (MET). In this review, we will revise the different biological and clinical aspects related to the use of PDGF pathway-targeted therapies in gastrointestinal cancers with particular focus on the future prospective in that regard.

Keywords

Imatinib Sunitinib Dovitinib PDGFR PDGF GI cancer 

Notes

Conflicts of interest

None.

Funding

This work has not been funded.

References

  1. 1.
    Abdel-Rahman O. Targeting vascular endothelial growth factor (VEGF) pathway in gastric cancer: preclinical and clinical aspects. Crit Rev Oncol/Hematol. 2014. doi: 10.1016/j.critrevonc.2014.05.012.Google Scholar
  2. 2.
    Venook AP, Papandreou C, Furuse J, de Guevara LL. The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. Oncologist. 2010;15(Supplement 4):5–13.CrossRefPubMedGoogle Scholar
  3. 3.
    Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRefPubMedGoogle Scholar
  4. 4.
    Kordes S, Cats A, Meijer SL, van Laarhoven HW. Targeted therapy for advanced esophagogastric adenocarcinoma. Crit Rev Oncol Hematol. 2014;90:68–76.CrossRefPubMedGoogle Scholar
  5. 5.
    Kasper S, Schuler M. Targeted therapies in gastroesophageal cancer. Eur J Cancer. 2014;50(7):1247–58. doi: 10.1016/j.ejca.2014.01.009.CrossRefPubMedGoogle Scholar
  6. 6.
    Alvarez RH, Kantarjian HM, & Cortes, JE. Biology of platelet-derived growth factor and its involvement in disease. In Mayo Clinic Proceedings. 2006; 81(9):1241–57. Elsevier.Google Scholar
  7. 7.
    Fantl WJ, Johnson DE, Williams LT. Signalling by receptor tyrosine kinases. Annu Rev Biochem. 1993;62:453–81.CrossRefPubMedGoogle Scholar
  8. 8.
    Terracio L, Ronnstrand L, Tingstrom A, et al. Induction of platelet derived growth factor receptor expression in smooth muscle cells and fibroblasts upon tissue culturing. J Cell Biol. 1988;107:1947–57.CrossRefPubMedGoogle Scholar
  9. 9.
    Type III RTKs: PDGFR, CSFR, Kit, FLT3 receptor family. IUPHAR database (IUPHAR-DB). 2014. http://www.iuphar-db.org/DATABASE/FamilyMenuForward?familyId=322. Accessed on 27 Oct 2014.
  10. 10.
    Huang F, Wang M, Yang T, Cai J, Zhang Q, Sun Z, et al. Gastric cancer-derived MSC-secreted PDGF-DD promotes gastric cancer progression. J Cancer Res Clin Oncol. 2014; 1–14Google Scholar
  11. 11.
    Kodama M, Kitadai Y, Sumida T, Ohnishi M, Ohara E, Tanaka M, et al. Expression of platelet‐derived growth factor (PDGF)‐B and PDGF‐receptor β is associated with lymphatic metastasis in human gastric carcinoma. Cancer Sci. 2010;101(9):1984–9.CrossRefPubMedGoogle Scholar
  12. 12.
    Drescher D, Moehler M, Gockel I, Frerichs K, Muller A, Dunschede F, et al. Coexpression of receptor-tyrosine-kinases in gastric adenocarcinoma-a rationale for a molecular targeting strategy? World J Gastroenterol. 2007;13(26):3605.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Gockel I, Moehler M, Frerichs K, Drescher D, Trinh TT, Duenschede F, et al. Co-expression of receptor tyrosine kinases in esophageal adenocarcinoma and squamous cell cancer. Oncol Rep. 2008;20(4):845.PubMedGoogle Scholar
  14. 14.
    Liu YC, Chen SC, Chang C, Leu CM, Hu CP. Platelet-derived growth factor is an autocrine stimulator for the growth and survival of human esophageal carcinoma cell lines. Exp Cell Res. 1996;228(2):206–11.CrossRefPubMedGoogle Scholar
  15. 15.
    Zhang JB, Sun HC, Jia WD, Zhuang PY, Qian YB, Zhu XD, et al. Up-regulation of platelet-derived growth factor-A is responsible for the failure of re-initiated interferon alpha treatment in hepatocellular carcinoma. BMC Cancer. 2012;12(1):439.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Maass T, Thieringer FR, Mann A, Longerich T, Schirmacher P, Strand D, et al. Liver specific overexpression of platelet‐derived growth factor‐B accelerates liver cancer development in chemically induced liver carcinogenesis. Int J Cancer. 2011;128(6):1259–68.CrossRefPubMedGoogle Scholar
  17. 17.
    Sillars-Hardebol AH, Carvalho B, de Wit M, Postma C, Delis-van Diemen PM, Mongera S, et al. Identification of key genes for carcinogenic pathways associated with colorectal adenoma-to-carcinoma progression. Tumor Biol. 2010;31(2):89–96.CrossRefGoogle Scholar
  18. 18.
    Sihto H, Franssila K, Tanner M, Vasama-Nolvi C, Sarlomo-Rikala M, Nupponen NN, et al. Platelet-derived growth factor receptor family mutations in gastrointestinal stromal tumours. Scand J Gastroenterol. 2006;41(7):805–11.CrossRefPubMedGoogle Scholar
  19. 19.
    Haller F, Happel N, Schulten HJ, von Heydebreck A, Schwager S, Armbrust T, et al. Site-dependent differential KIT and PDGFRA expression in gastric and intestinal gastrointestinal stromal tumors. Mod Pathol. 2007;20(10):1103–11.CrossRefPubMedGoogle Scholar
  20. 20.
    Du CY, Shi YQ, Zhou YE, Fu H, Zhao G. The analysis of status and clinical implication of KIT and PDGFRA mutations in gastrointestinal stromal tumor (GIST). J Surg Oncol. 2008;98(3):175–8.CrossRefPubMedGoogle Scholar
  21. 21.
    Miettinen M, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol. 2005;29(1):52–68.CrossRefPubMedGoogle Scholar
  22. 22.
    Guo Y, Yin J, Zha L, Wang Z. Clinicopathological significance of platelet-derived growth factor B, platelet-derived growth factor receptor-β, and E-cadherin expression in gastric carcinoma. Contemp Oncol (Pozn). 2013;17(2):150–5.Google Scholar
  23. 23.
    Kurokawa Y, Matsuura N, Kawabata R, Nishikawa K, Ebisui C, Yokoyama Y, et al. Prognostic impact of major receptor tyrosine kinase expression in gastric cancer. Ann of Surg Oncol. 2014; 1–7.Google Scholar
  24. 24.
    Suzuki S, Dobashi Y, Hatakeyama Y, Tajiri R, Fujimura T, Heldin CH, et al. Clinicopathological significance of platelet-derived growth factor (PDGF)-B and vascular endothelial growth factor-A expression, PDGF receptor-β phosphorylation, and microvessel density in gastric cancer. BMC Cancer. 2010;10(1):659.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Yuzawa S, Kano MR, Einama T, Nishihara H. PDGFRβ expression in tumor stroma of pancreatic adenocarcinoma as a reliable prognostic marker. Med Oncol. 2012;29(4):2824–30.CrossRefPubMedGoogle Scholar
  26. 26.
    Chu JS, Ge FJ, Zhang B, Wang Y, Silvestris N, Liu LJ, et al. Expression and prognostic value of VEGFR-2, PDGFR-β, and c-Met in advanced hepatocellular carcinoma. J Exp Clin Cancer Res. 2013;32(16):234–56.Google Scholar
  27. 27.
    Chen L, Shi Y, Jiang CY, Wei LX, Lv YL, Wang YL, et al. Coexpression of PDGFR-alpha, PDGFR-beta and VEGF as a prognostic factor in patients with hepatocellular carcinoma. Int J Biol Markers. 2010;26(2):108–16.CrossRefGoogle Scholar
  28. 28.
    Kitadai Y, Sasaki T, Kuwai T, Nakamura T, Bucana CD, Hamilton SR, et al. Expression of activated platelet‐derived growth factor receptor in stromal cells of human colon carcinomas is associated with metastatic potential. Int J Cancer. 2006;119(11):2567–74.CrossRefPubMedGoogle Scholar
  29. 29.
    Søreide K, Sandvik OM, Søreide JA, Gudlaugsson E, Mangseth K, Haugland HK. Tyrosine-kinase mutations in c-KIT and PDGFR-alpha genes of imatinib naïve adult patients with gastrointestinal stromal tumours (GISTs) of the stomach and small intestine: relation to tumour-biological risk-profile and long-term outcome. Clin Transl Oncol. 2012;14(8):619–29.CrossRefPubMedGoogle Scholar
  30. 30.
    Cassier PA, Fumagalli E, Rutkowski P, Schöffski P, Van Glabbeke M, Debiec-Rychter M, et al. Outcome of patients with platelet-derived growth factor receptor alpha-mutated gastrointestinal stromal tumors in the tyrosine kinase inhibitor era. Clin Cancer Res. 2012;18(16):4458–64.CrossRefPubMedGoogle Scholar
  31. 31.
    Emile JF, Brahimi S, Coindre JM, Bringuier PP, Monges G, Samb P, et al. Frequencies of KIT and PDGFRA mutations in the MolecGIST prospective population-based study differ from those of advanced GISTs. Med Oncol. 2012;29(3):1765–72.CrossRefPubMedGoogle Scholar
  32. 32.
    Heldin CH. Targeting the PDGF signaling pathway in tumor treatment. Cell Commun Signal. 2013;11(1):97.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Abdel-Rahman O, Fouad M. Risk of cardiovascular toxicities in patients with solid tumors treated with sunitinib, axitinib, cediranib or regorafenib: an updated systematic review and comparative meta-analysis. Crit Rev Oncol Hematol. 2014. doi: 10.1016/j.critrevonc.2014.06.003.
  34. 34.
    Abdel-Rahman O, Fouad M. Risk of thyroid dysfunction in patients with solid tumors treated with VEGF receptor tyrosine kinase inhibitors: a critical literature review and meta analysis. Expert Rev Anticancer Ther. 2014;14(9):1063–73. doi: 10.1586/14737140.2014.929501.CrossRefPubMedGoogle Scholar
  35. 35.
    Peng, Y., Guo, J. J., Liu, Y. M., & Wu, X. L. MicroRNA-34a inhibits the growth, invasion and metastasis of gastric cancer by targeting PDGFR and MET expression. Biosci Rep. 2014;34(3). doi: 10.1042/BSR20140020.
  36. 36.
    Rajkumar VS, Boxer G, Robson M, Muddle J, Papastavrou Y, Pedley RB. A comparative study of PDGFR inhibition with imatinib on radiolabeled antibody targeting and clearance in two pathologically distinct models of colon adenocarcinoma. Tumor Biol. 2012;33(6):2019–29.CrossRefGoogle Scholar
  37. 37.
    Yamamoto M, Kikuchi H, Ohta M, Kawabata T, Hiramatsu Y, Kondo K, et al. TSU68 prevents liver metastasis of colon cancer xenografts by modulating the premetastatic niche. Cancer Res. 2008;68(23):9754–62.CrossRefPubMedGoogle Scholar
  38. 38.
    Kitadai Y, Sasaki T, Kuwai T, Nakamura T, Bucana CD, Fidler IJ. Targeting the expression of platelet-derived growth factor receptor by reactive stroma inhibits growth and metastasis of human colon carcinoma. Am J Pathol. 2006;169(6):2054–65.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Shinagawa K, Kitadai Y, Tanaka M, Sumida T, Onoyama M, Ohnishi M, et al. Stroma‐directed imatinib therapy impairs the tumor‐promoting effect of bone marrow‐derived mesenchymal stem cells in an orthotopic transplantation model of colon cancer. Int J Cancer. 2013;132(4):813–23.CrossRefPubMedGoogle Scholar
  40. 40.
    Yoon YK, Im SA, Min A, Kim HP, Hur HS, Lee KH, et al. Sunitinib synergizes the antitumor effect of cisplatin via modulation of ERCC1 expression in models of gastric cancer. Cancer Lett. 2012;321(2):128–36.CrossRefPubMedGoogle Scholar
  41. 41.
    Taeger J, Moser C, Hellerbrand C, Mycielska ME, Glockzin G, Schlitt HJ, et al. Targeting FGFR/PDGFR/VEGFR impairs tumor growth, angiogenesis, and metastasis by effects on tumor cells, endothelial cells, and pericytes in pancreatic cancer. Mol Cancer Ther. 2011;10(11):2157–67.CrossRefPubMedGoogle Scholar
  42. 42.
    Huynh H, Chow PKH, Tai WM, Choo SP, Chung AYF, Ong HS, et al. Dovitinib demonstrates antitumor and antimetastatic activities in xenograft models of hepatocellular carcinoma. J Hepatol. 2012;56(3):595–601.CrossRefPubMedGoogle Scholar
  43. 43.
    Ohta M, Kawabata T, Yamamoto M, Tanaka T, Kikuchi H, Hiramatsu Y, et al. TSU68, an antiangiogenic receptor tyrosine kinase inhibitor, induces tumor vascular normalization in a human cancer xenograft nude mouse model. Surg Today. 2009;39(12):1046–53.CrossRefPubMedGoogle Scholar
  44. 44.
    Garner, AP, Gozgit JM, Anjum R, Vodala S, Schrock A, Zhou T, et al. Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients. Clin Cancer Res. 2014.doi: 10.1158/1078-0432.
  45. 45.
    Sako H, Fukuda K, Saikawa Y, Nakamura R, Takahashi T, Wada N, et al. Antitumor effect of the tyrosine kinase inhibitor nilotinib on gastrointestinal stromal tumor (GIST) and imatinib-resistant GIST cells. PLoS One. 2014;9(9):e107613.CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Mayr M, Becker K, Schulte N, Belle S, Hofheinz R, Krause A, et al. Phase I study of imatinib, cisplatin and 5-fluoruracil or capecitabine in advanced esophageal and gastric adenocarcinoma. BMC Cancer. 2012;12(1):587.CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Kang YK, Ryu MH, Yoo C, Ryoo BY, Kim HJ, Lee JJ, et al. Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2013;14(12):1175–82.CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Moehler M, Mueller A, Hartmann JT, et al. An open-label, multicentre biomarker-oriented AIO phase II trial of sunitinib for patients with chemo-refractory advanced gastric cancer. Eur J Cancer. 2011;10:1511–20.CrossRefGoogle Scholar
  49. 49.
    Yi JH, Lee J, Lee J, et al. Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum. Br J Cancer. 2012;106(9):1469–74.CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Dragovich T, Laheru D, Dayyani F, Bolejack V, Smith L, Seng J, et al. Phase II trial of vatalanib in patients with advanced or metastatic pancreatic adenocarcinoma after first-line gemcitabine therapy (PCRT O4-001). Cancer Chemother Pharmacol. 2014;74(2):379–87.CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Bruix J, Tak WY, Gasbarrini A, Santoro A, Colombo M, Lim HY, et al. Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study. Eur J Cancer. 2013;49(16):3412–9.CrossRefPubMedGoogle Scholar
  52. 52.
    Starling N, Hawkes EA, Chau I, Watkins D, Thomas J, Webb J, et al. A dose escalation study of gemcitabine plus oxaliplatin in combination with imatinib for gemcitabine-refractory advanced pancreatic adenocarcinoma. Ann Oncol. 2012;23(4):942–7. doi: 10.1093/annonc/mdr317.CrossRefPubMedGoogle Scholar
  53. 53.
    Cainap C, Qin S, Huang WT, Chung IJ, Pan H, Cheng Y, et al. (2013). Phase III trial of linifanib versus sorafenib in patients with advanced hepatocellular carcinoma (HCC). In J Clin Oncol 31(4).Google Scholar
  54. 54.
    Shin SJ, Jung M, Jeung HC, Kim HR, Rha SY, Roh JK, et al. A phase I pharmacokinetic study of TSU-68 (a multiple tyrosine kinase inhibitor of VEGFR-2, FGF and PDFG) in combination with S-1 and oxaliplatin in metastatic colorectal cancer patients previously treated with chemotherapy. Invest New Drugs. 2012;30(4):1501–10.CrossRefPubMedGoogle Scholar
  55. 55.
    Grothey A, Cutsem EV, Sobrero A, Siena S, Falcone A, Ychou M, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381(9863):303–12.CrossRefPubMedGoogle Scholar
  56. 56.
    Joensuu H, Eriksson M, Hall KS, Hartmann JT, Pink D, Schütte J, et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. Jama. 2012;307(12):1265–72.CrossRefPubMedGoogle Scholar
  57. 57.
    Blay JY, Le Cesne A, Ray-Coquard I, Bui B, Duffaud F, Delbaldo C, et al. Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. J Clin Oncol. 2007;25(9):1107–13.CrossRefPubMedGoogle Scholar
  58. 58.
    Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006;368(9544):1329–38.CrossRefPubMedGoogle Scholar
  59. 59.
    Ganjoo KN, Villalobos VM, Kamaya A, Fisher GA, Butrynski JE, Morgan JA, et al. A multicenter phase II study of pazopanib in patients with advanced gastrointestinal stromal tumors (GIST) following failure of at least imatinib and sunitinib. Ann Oncol. 2014;25(1):236–40.CrossRefPubMedPubMedCentralGoogle Scholar
  60. 60.
    Demetri GD, Reichardt P, Kang YK, Blay JY, Rutkowski P, Gelderblom H, et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381(9863):295–302.CrossRefPubMedGoogle Scholar
  61. 61.
    Kang YK, Yoo C, Ryoo BY, Lee JJ, Tan E, Park I, et al. Phase II study of dovitinib in patients with metastatic and/or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib. Br J Cancer. 2013;109(9):2309–15.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  1. 1.Clinical Oncology Department, Faculty of MedicineAin Shams UniversityCairoEgypt

Personalised recommendations